Hotgen CLIA Analyzer Empowering Precision Cancer Diagnosis and Treatment

In the field of cancer prevention and treatment, tumor markers act like "signal lights" hidden within the body. When cells undergo malignant transformation, fluctuations in the concentration of these specific substances provide early warning signals to physicians. In vitro diagnostic (IVD) technologies, by precisely capturing these "signals", are gradually reshaping the landscape of cancer diagnosis and treatment, facilitating early detection and personalized therapy.

Tumor Markers: The "Leakage Code" of Tumor Cells

Tumor markers are specific substances either produced by tumor cells themselves or released by the body in response to tumor development. They are widely present in blood, bodily fluids, and tissues. For example, alpha-fetoprotein (AFP) is an important marker for hepatocellular carcinoma; its level is very low in healthy individuals but can increase dozens or even hundreds of times in the blood of liver cancer patients. In addition, various other markers—such as carbohydrate antigens like CA125 (closely related to ovarian cancer), enzymes like prostate-specific antigen (PSA), hormones, and tumor-associated gene fragments—reflect the biological characteristics of tumors and serve as crucial bases for precise diagnosis and efficacy evaluation.

CLIA (Chemiluminescent Immunoassay): The "Eagle Eye" for Accurately Decoding Tumor Signals

If tumor markers are the inadvertent "leakage codes" left behind by tumor cells, then CLIA (chemiluminescent immunoassay) technology in IVD is the key tool for deciphering these codes. CLIA utilizes the highly specific binding between antibodies and markers, producing luminescent signals through chemical reactions to sensitively detect trace amounts of tumor markers. It offers advantages such as high sensitivity, high specificity, and automation, making it one of the mainstream technologies in modern clinical testing.

Hotgen MQ60 Series CLIA Analyzer: Empowering Multidimensional Precision Diagnosis

As a leading manufacturer in the field of CLIA analyzers, Hotgen has launched the MQ60 series of mono-test CLIA immunoassay analyzers, including the MQ60 smart, MQ60 pro, and MQ60 plus models. This comprehensive product line caters to testing scenarios across various scales—from grassroots healthcare facilities to large tertiary hospitals. The MQ60 series, known for its outstanding performance, has gained widespread global recognition, with cumulative installations exceeding 10,000 units.

Paired with Hotgen's independently developed CLIA reagents, the MQ60 chemiluminescence immunoassay analyzers support high-precision diagnostics for cardiovascular diseases, inflammation, tumors, thyroid function, hormone-related disorders, anemia, diabetes, hypertension, rheumatoid arthritis, and more. The range of detectable parameters continues to expand, now covering over 100 indicators to meet diverse clinical needs.

Advantages of the Hotgen MQ60 Series CLIA Analyzer

Precision and Reliability

The advanced chemiluminescent diagnostic platform ensures highly stable results with low coefficient of variation (CV), supported by an independent quality control system. The single-reagent design prevents cross-contamination, ensuring test accuracy.

Cost-Effectiveness

Single-sample reagent packaging minimizes reagent waste and reduces costs associated with expired vial reagents. The analyzer's design excludes liquid handling systems, simplifying maintenance and lowering failure rates, thereby significantly reducing operational costs.

Comprehensive and Extensive

Supports over 100 test items spanning more than 20 major clinical diagnostic categories, meeting the integrated needs of multiple clinical departments and diverse disease types.

Flexible Compatibility

Allows free combination of testing parameters and supports multiple sample types including whole blood, serum, plasma, and urine, adapting to various clinical sample requirements.

Hotgen is committed to empowering clinical diagnostics with cutting-edge CLIA technology, advancing early screening, diagnosis, and precision treatment of tumors and various major diseases. Through continuous innovation, Hotgen is collaborating with healthcare institutions to build a more efficient and reliable in vitro diagnostic ecosystem, propelling global health efforts to new heights.